Pharmacotherapy Trials in Posttraumatic Stress Disorder: Prospects and Problems

  • Bernard Lerer
  • Peter Braun
  • Avraham Bleich
  • Haim Dasberg
  • David Greenberg


Although a clinical symptom picture resembling the currently accepted DSM-III diagnosis of posttraumatic stress disorder (PTSD) has been recognized for decades, focused trials of psychopharmacological agents are a relatively recent development. The initial report by Hogben and Cornfield1 of a dramatic effect of treatment with the monoamine oxidase inhibitor phenelzine in patients with “traumatic war neurosis” has been followed by a spate of positive reports. These reports have attributed beneficial effects to a variety of drugs including tricyclic antidepressants,2,3 the limbic anticonvulsant carbamazepine,4 and the β-receptor blocker propranolol.5 Contrary to these generally optimistic reports, our experience with psychotropic agents in Israeli samples of PTSD patients has been less encouraging. This experience has been for the most part prospective and, in two studies, double-blind in nature using a drug/placebo crossover design.


Ptsd Symptom Panic Disorder Post Traumatic Stress Disorder Ptsd Patient Psychotropic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hogben GL, Cornfield RB. Treatment of traumatic war neurosis with phenelzine. Arch Gen Psychiatry 1981; 38: 440 – 445.PubMedGoogle Scholar
  2. 2.
    Falcon S, Ryan C, Chamberlain K, et al. Tricyclics: possible treatment for posttraumatic stress disorder. J Clin Psychiatry 1985; 46: 385 – 389.PubMedGoogle Scholar
  3. 3.
    Burstein A. The treatment of post-traumatic stress disorder with imipramine. Psychosomatics 1983; 25: 683 – 687.Google Scholar
  4. 4.
    Wolf ME, Alavi A, Mosanaim AD. Post traumatic stress disorder in Vietnam veterans’ clinical and EEG findings: possible therapeutic effects of carbamazepine. Biol Psychiatry 19878 press.Google Scholar
  5. 5.
    Kolb LC, Burris BC, Griffiths S. Propanolol and clonidine in treatment of the chronic post traumatic stress disorders of war. In van der Kolk B (ed): Post Traumatic Stress Disorder: Psychological and Biological Sequelae. Washington, DC: American Psychiatric Press, 1984; 97 – 105.Google Scholar
  6. 6.
    Lerer B, Bleich A, Garb R, et al. Post traumatic stress disorder in Israeli combat veterans: effect of phenelzine treatment. Arch Gen Psychiatry 1987; 44: 976 – 981.PubMedGoogle Scholar
  7. 7.
    Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in post traumatic stress disorder. Psychiatry Res 1987; 24: 149 – 155.CrossRefGoogle Scholar
  8. 8.
    Fawcett JA, Kravitz HM. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacotherapy 1982; 2: 243 – 254.PubMedGoogle Scholar
  9. 9.
    Braun P, Greenberg D, Lerer B. Modest effects of alprazolam on anxiety symptoms in post traumatic stress disorder. Submitted for publication.Google Scholar
  10. 10.
    Bleich A, Siegel R, Garb R, et al. Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment. Br J Psychiatry 1986; 149: 365 – 369.PubMedCrossRefGoogle Scholar
  11. 11.
    Davidson J, Walker JI, Kilts C. A pilot study of phenelzine in post-traumatic stress disorder. Br J Psychiatry 1987; 150: 252 – 255.PubMedCrossRefGoogle Scholar
  12. 12.
    Marshall JR: The treatment of night terrors associated with the posttraumatic syndrome. Am J Psychiatry 1975; 132: 293 – 295.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • Bernard Lerer
  • Peter Braun
  • Avraham Bleich
  • Haim Dasberg
  • David Greenberg

There are no affiliations available

Personalised recommendations